Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-3.34% $0.148
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 6.53 mill |
EPS: | -0.980 |
P/E: | -0.150 |
Earnings Date: | May 09, 2024 |
SharesOutstanding: | 44.26 mill |
Avg Daily Volume: | 5.45 mill |
RATING 2024-03-28 |
---|
A+ |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Sell | |
P/E: | Strong Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.150 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.150 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.168 (14.13%) $0.0208 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 0.133 - 0.165 ( +/- 10.72%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Fortress Biotech, Inc. | Buy | 2 101 496 | COMMON STOCK, PAR VALUE $0.0001 |
2023-12-11 | Davidow Robert L | Sell | 264 000 | Common Stock |
2023-12-11 | Davidow Robert L | Sell | 126 000 | Common Stock |
2023-12-11 | Davidow Robert L | Sell | 128 000 | Common Stock |
2023-12-11 | Davidow Robert L | Sell | 20 000 | Common Stock |
INSIDER POWER |
---|
69.55 |
Last 83 transactions |
Buy: 6 354 200 | Sell: 1 021 576 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.148 (-3.34% ) |
Volume | 0.791 mill |
Avg. Vol. | 5.45 mill |
% of Avg. Vol | 14.52 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.